Ultra-processed food compounds and their possible role in eosinophilic esophagitis
Looks at diet and ultra-processed food compounds in people with eosinophilic esophagitis.
Key facts
- Who runs it
- Federico II University
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 12 Apr 2023
- Expected to end
- 12 Jun 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Dietary evaluation
- Record updated
- 1 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a confirmed diagnosis of eosinophilic esophagitis, and healthy people of the same age and sex for comparison. It studies diet and ultra-processed foods.
- Age
- 3 to 65 years
- Sex
- All sexes
- Disease stage
- A confirmed diagnosis of eosinophilic esophagitis (for the patient group).
Main reasons for not taking part
- Not of Caucasian ethnicity
- Other eosinophilic gut diseases, achalasia, GERD, IBD or hypereosinophilia syndrome
- Autoimmune diseases, connective tissue disorders, vasculitis, or fungal or viral infections
- Drug hypersensitivity reactions, drug-induced oesophagitis, graft vs host disease or certain genetic disorders (Marfan syndrome type 2, HIES, PTEN)
- Tattoos, scars, moles or particular skin lesions on both forearms
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- both sexes
- age between 3-65 years
- sure diagnosis of eosinophilic esophagitis
- age- and sex-matched healthy controls
- parents/tutor written informed consent
Who cannot take part
- simultaneous presence of other chronic diseases: eosinophilic gastroenteritis, eosinophilic colitis, achalasia, GERD, hypereosinophilia syndrome, IBD, fungal or viral infections, connective tissue disorders, autoimmune diseases, vasculitis, bullous dermatosis with oesophageal involvement (pemphigus), drug hypersensitivity reactions, drug-induced oesophagitis, graft vs host disease, monogenic disorders (Marfan syndrome type 2, HIES, PTEN)
- age at enrollment < 3 or >65 years
- lack of written informed consent
- non-Caucasian ethnicity
- presence of tattoos, scars, moles or particular lesions on both forearms
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 3 and 65 years old?
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Eosinophilic esophagitis (EoE) is a chronic antigen-mediated inflammatory disease of the esophagus that affects both children and adults. The incidence and prevalence of EoE is rapidly increasing in Western countries with an estimated incidence of 6.6 per 100,000 person-years (95% CI, 3-11.7) in children and 7.7 per 100,000 person-years (95% CI, 1.8-17.8) in adults. Clinically, it is characterized by various symptoms related to esophageal dysfunction, including vomiting, regurgitation, feeding difficulties, epigastric heartburn, dysphagia, or food bolus impaction, and may cause growth retardation. Diagnosis is made on the basis of clinical symptoms and histological evidence of eosinophilic infiltration of the esophagus (at least 15 eosinophils/high power microscope field (eos /hpf), excluding other etiologies of esophageal eosinophilia (gastroesophageal reflux disease, infectious esophagitis, achalasia, celiac disease and Crohn's disease, connective tissue disorders, gra ft versus host disease, drug hypersensitivity and hypereosinophilic syndromes). EoE is primarily characterized by a T helper 2 type inflammation, but the pathogenesis and the immunopathological mechanisms underlying the pathology are not yet fully understood. Recent evidence suggests that in genetically predisposed individuals, interaction with environmental factors (e.g., dietary lifestyle) may play a role in activating several inflammatory pathways and cause EoE.
Read full original descriptionShow less
Ultra-processed foods (UPFs) are food and beverage products resulting from industrial formulations, ready for consumption, typically obtained with five or more ingredients from different manufacturing processes (cooking methods, addition of additives such as stabilizers or preservatives). During the last decade, the consumption of the latter has increased significantly among the pediatric population to represent 30% of the daily caloric intake of an average child in Europe and America. Recent evidences show that UPFs favor the onset of chronic non-communicable diseases through the activation of different inflammatory pathways.
The components mostly represented in UPFs are the advanced glycation end products (AGEs), a heterogeneous group of highly oxidizing compounds that are formed through non-enzymatic reactions (Maillard reaction) between reduced sugars and free amino groups of proteins, lipids, or nucleic acids.
Evidence demonstrates that dietary AGEs are absorbed and contribute significantly to the total concentration of AGEs in the body. AGEs induce oxidative stress and inflammation, leading to structural and functional protein alterations, cellular apoptosis and multi-tissue/organ damage. These mechanisms are mediated at least in part by interactions with their cell-surface receptor for advanced glycation end-products (RAGE).
The AGEs-RAGE interaction modulates the immune response. AGEs are able to activate le mast cells, to stimulate the release of histamine and to induce a chronic inflammatory state that promotes a T helper 2 type response.
The 2 groups in the trial
- Patients with eosinophilic esophagitis
Patients with a sure diagnosis of eosinophilic esophagitis
Treatment: Dietary evaluation
- Sex and age matched healthy controls
Matched healthy controls for age and gender, without eosinophilic esophagitis
Treatment: Dietary evaluation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis
- Plain-language title
- Ultra-processed food compounds and their possible role in eosinophilic esophagitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06093204, who can take part
- Record updated
- 1 September 2026